Clinical Trial Update: Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Phase 2 single-dose trial of GW856553 in rheumatoid arthritis has completed, evaluating its effect on a disease biomarker.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GW856553

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED